News of Note—Zynerba repeat failure, Fortress spinoff, CEL-SCI lift and more

> A week after Zynerba saw its cannabinoid treatment miss all of its endpoints in epilepsy, it has followed up with a flop in a phase 2 for osteoarthritis with knee pain. “The study did not meet its primary endpoint of reduction from baseline in the weekly mean of the 24-hour average worst pain score at week 12,” the company said, but added there were some glimmers from a “number of secondary endpoints.” Release.

> Fortress Biotech has formed a subsidiary company, Aevitas Therapeutics, to work on new gene therapy approaches for complement-mediated diseases. Its technology, licensed from a “leading university,” could be used toward atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. Statement.

> After nearly a year, the FDA has told microcap CEL-SCI that the clinical hold on its phase 3 cancer test with Multikine (leukocyte interleukin) has been removed, and that all clinical trials with the medication under the IND can now fully restart. Release.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> Peregrine will swing the ax on 60 staffers (20% of its workforce) as part of its “series of planned strategic actions to reduce costs and better position the company to achieve overall profitability,” as it also looks out for strategic options for its R&D work. Statement.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.